ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions.
Kwekkeboom
Dik J
DJ
Department of Nuclear Medicine, Erasmus University Medical Center, NL-3015 Rotterdam, The Netherlands. d.j.kwekkeboom@erasmusmc.nl
Krenning
Eric P
EP
Lebtahi
Rachida
R
Komminoth
Paul
P
Kos-Kudła
Beata
B
de Herder
Wouter W
WW
Plöckinger
Ursula
U
D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D011878:Radiotherapy / Q000379:methods; D018000:Receptors, Peptide / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives*
D011868:Radioisotopes; D018000:Receptors, Peptide; D013004:Somatostatin